This inventor holds 2 USPTO granted patents. Top assignee: The UAB Research Foundation (The University of Alabama at Birmingham). Active years: 2004-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004-2006
Title: Kevin Paul Raisch: Innovator in Anti-Epidermal Growth Factor Receptor Antibodies
Introduction
Kevin Paul Raisch is a notable inventor based in Birmingham, AL (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting the epidermal growth factor receptor (EGFR). With a total of two patents to his name, Raisch's work has the potential to impact therapeutic and diagnostic applications.
Latest Patents
Raisch's latest patents focus on human anti-epidermal growth factor receptor single-chain antibodies. These antibodies were isolated from a human IgM phage display library using purified epidermal growth factor receptor as the antigen. Two isolates with different amino acid sequences were identified by ELISA as specific to the epidermal growth factor receptor. The single-chain variable fragments (scFvs) bind to both the full-length epidermal growth factor receptor and its truncated or mutated forms on human cells. These anti-EGFR-scFvs are poised to be useful as therapeutic and diagnostic agents.
Career Highlights
Kevin Paul Raisch is associated with the UAB Research Foundation, where he continues to advance his research in the field of biotechnology. His innovative work has garnered attention and recognition within the scientific community.
Collaborations
Raisch has collaborated with esteemed colleagues such as David T. Curiel and James Alan Bonner. These partnerships have contributed to the advancement of his research and the development of his patented technologies.
Conclusion
Kevin Paul Raisch is a prominent inventor whose work on anti-epidermal growth factor receptor antibodies holds promise for future therapeutic and diagnostic applications. His contributions to biotechnology are noteworthy and reflect his commitment to innovation in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile